01:25 PM EDT, 04/10/2025 (MT Newswires) -- Immunic ( IMUX ) said Thursday it closed its direct offering of about 5.67 million shares at $0.90 apiece, led by Aberdeen Investments.

Immunic ( IMUX ) said it plans to use the proceeds for clinical trials, operations and general corporate purposes. American Capital Partners division, Titan Partners Group, was the placement agent.

Price: 0.89, Change: -0.04, Percent Change: -4.27